Advanced Search
Current and Breaking News for Professionals, Consumers and Media

Click here to learn how to advertise on this site and for ad rates.

Cancer Issues Author: Staff Editor Last Updated: Sep 7, 2017 - 10:06:33 PM

Promising New Lung Cancer Treatment

By Staff Editor
Jan 21, 2014 - 2:20:34 PM

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust

Email this article
 Printer friendly page

( - MORGANTOWN, W.Va. - A clinical research study at the West Virginia University Mary Babb Randolph Cancer Center offers hope to patients with advanced early-stage non-small cell lung cancer.

Alexander Chi, M.D., assistant professor in the WVU Department of Radiology Oncology, is leading the study, which involves stereotactic ablative radiotherapy (SABR) - a new and increasingly utilized radiation therapy used to treat early-stage non-small cell lung cancer and isolated recurrent non-small cell lung cancer.

Dr. Chi, an associate member of the Cancer Center's Sara Crile Allen and James Frederick Allen Lung Cancer Program, said SABR has already been proven successful in treating early stage non-small cell lung cancer.  His current study seeks to evaluate the effectiveness of escalated doses of SABR for lung cancer patients with more advanced early-stage lung cancer.

"These patients, who have received an ablative dose of radiation over a course of a few days, have had excellent clinical outcomes," he said. "However, it is not yet known what the most appropriate dose of SABR is to effectively treat those with more advanced early-stage lung cancer."

Chi is optimistic that patients who participate in the study will benefit. 

"It is very possible that the escalated doses of SABR will be able to cure the disease in 80 percent of the patients," he said. "In the remaining 20 percent, whose cancer is likely to recur beyond the chest wall, SABR will still help delay the cancer's spread."

A second purpose of the study is to establish a set of potential predictive biomarkers in blood and tumor tissue to identify patients who would benefit from high-dose SABR alone and those at high risk for lung cancer recurrence who will need additional chemotherapy.

"The results of this research study will contribute to strategies aimed at individualizing treatments for patients with non-small cell lung cancer," Chi said. 

"The Department of Radiation Oncology has acquired and implemented new technology that improves our ability to deliver precise treatments," Geraldine Jacobson, M.D., chair of the Department of Radiation Oncology, said. "These include on-board imaging for accurate daily treatments, RapidArc for fast and precise delivery, and stereotactic body radiation (SBRT), which allows us to treat small lung cancers and other small tumors in less than a week. We have also implemented breath-hold treatments for left-sided breast cancer, which can reduce the radiation dose to the heart. Our philosophy is to continue to advance our capability to provide precise, rapid, and safe radiation therapy to our patients."

For more information on the WVU Department of Radiation Oncology, see


For advertising and promotion on, call Mike McCurdy: 877-634-9180 or [email protected] We have over 7,000 journalists as subscribers.


Top of Page

Cancer Issues
Latest Headlines

+ How Defeating THOR Could Bring a Hammer Down on Cancer
+ Skin Cancer Treatment Selfie Goes Viral, Has Public Health Lessons
+ Researchers Develop Test That Can Diagnose Two Cancer Types
+ Spot Check: Sorting Out Freckles, Moles, and Skin Cancer
+ Safety Net Hospitals: Are the Uninsured Getting Good Quality Cancer Care?
+ Cancer Survivors and Financial Stress: The Hidden Secret No One Discusses
+ Medical Marijuana for Children with Cancer? What Providers Think
+ Emojis Promising Tool for Tracking Cancer Patients’ Quality of Life
+ CAR T, Immunotherapy Bring New Hope for Multiple Myeloma Patients
+ Soy, Cruciferous Vegetables Associated with Fewer Common Side Effects of Breast Cancer Treatment

Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions